➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,707,182

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,707,182 protect, and when does it expire?

Patent 9,707,182 protects ORTIKOS and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 9,707,182
Title:Oral pharmaceutical dosage forms of budesonide
Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.
Inventor(s): Thennati; Rajamannar (Baroda, IN), Kulkarni; Shirish (Baroda, IN), Kulkarni; Amol (Baroda, IN), Kaneria; Vimal (Bopal, IN), Sharma; Mukesh (Baroda, IN)
Assignee: Sun Pharmaceutical Industries LTD. (Maharashtra, IN)
Application Number:15/261,420
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 9,707,182

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharma Global ORTIKOS budesonide CAPSULE, EXTENDED RELEASE;ORAL 211929-001 Jun 13, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sun Pharma Global ORTIKOS budesonide CAPSULE, EXTENDED RELEASE;ORAL 211929-002 Jun 13, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,707,182

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India3498/MUM/2015Sep 11, 2015

International Family Members for US Patent 9,707,182

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3346996   Start Trial
Japan 2018530535   Start Trial
World Intellectual Property Organization (WIPO) 2017042835   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.